| Current Price | $86.15 | Mkt Cap | $15.4B |
|---|---|---|---|
| Open | $88.39 | P/E Ratio | 0.00 |
| Prev. Close | $85.63 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $85.42 - $88.88 | Volume | 1,214,680 |
| 52-Wk Range | $82.83 - $93.14 | Avg. Daily Vol. | 1,297,195 |
The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
| Current Price | $86.15 | Mkt Cap | $15.4B |
|---|---|---|---|
| Open | $88.39 | P/E Ratio | 0.00 |
| Prev. Close | $85.63 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $85.42 - $88.88 | Volume | 1,214,680 |
| 52-Wk Range | $82.83 - $93.14 | Avg. Daily Vol. | 1,297,195 |
The best Bull and Bear pitches based on recency and number of recommendations.
The global target market for Morquio syndrome patients with ability to pay for treatment is around 2500 patients. ThinkEquity analyst Kimberly Lee estimates the market potential of GALNS at 575 million annually. This would be $230,000 annually per… More
Read the most recent pitches from players about BMRN.
Recs
TMFEBCapital
(88.14)
Submitted: 6/7/2018 9:49:55 AM :
Start Price:
$92.15
NASDAQ:BMRN Score:
-24.57
Palynziq could address more PKU patients than BMRN's Kuvan (its second best-seller) and that means 400 mn plus in annual revenue. Mgmt thinks that if it's widely adopted, it's peak sales could be $1 bn. Given BMRN's sales of 1.3 billion in 2017, that represents a significant potential increase that could finally get this company in the black. The big kicker here, though, is the hemophilia A R&D program, which could have data as soon as next year. A win there would revolutionize treatment and potentially, relegate prophylaxis factor VII replacement to the past.
Recs
TMFSaintCroix
(99.41)
Submitted: 1/14/2018 3:14:30 PM :
Start Price:
$84.41
NASDAQ:BMRN Score:
-43.17
These guys have found a cure for hemophilia. 400,000 people with hemophilia in the world. And BioMarin and Spark are going to make this disease gone.
Wow. Kudos. Outperform.
Recs
OleSmoky
(79.57)
Submitted: 1/9/2017 10:14:43 PM :
Start Price:
$91.31
NASDAQ:BMRN Score:
-50.68
Pricy, but I believe this has a bright future for those who are patient.
Find the members with the highest scoring picks in BMRN.
Jmcq88 (85.13) Score: +758.20
The Score Leader is the player with the highest score across all their picks in BMRN.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| BreakerBeth | 95.51 | 5/17/2006 |
|
5Y | $12.26 | +603.18% | +173.78% | +429.40 | 1 Comment | |
| RBBioContest06 | 60.46 | 6/1/2006 |
|
1Y | $13.05 | +560.61% | +176.19% | +384.42 | 1 Comment | |
| GlobalTraveler | 79.63 |
|
|
3Y | $10.04 | +758.67% | +385.88% | +372.78 | 0 Comment | |
| kaywonder | < 20 |
|
|
5Y | $10.11 | +752.72% | +389.21% | +363.51 | 0 Comment | |
| vacafun4 | 94.47 | 3/6/2009 |
|
3Y | $10.18 | +746.86% | +389.57% | +357.29 | 0 Comment | |
| makednoc | < 20 |
|
|
3Y | $10.29 | +737.80% | +384.70% | +353.11 | 0 Comment | |
| DamYankee | < 20 | 9/29/2006 |
|
1Y | $14.41 | +498.27% | +160.73% | +337.53 | 0 Comment | |
| MellieMel777 | 47.41 | 9/29/2006 |
|
3Y | $14.41 | +498.27% | +160.73% | +337.53 | 1 Comment | |
| geolitjon | < 20 | 4/6/2009 |
|
5Y | $12.00 | +618.42% | +298.24% | +320.17 | 0 Comment | |
| rolloro | 43.89 | 10/2/2006 |
|
3Y | $15.00 | +474.73% | +161.23% | +313.50 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
